Pharma BD Deal Intelligence
The $450M Lafon buyout gave Cephalon full worldwide rights to modafinil (Provigil), which grew into a $1B+/year franchise and became the centerpiece of Teva's later $6.8B acquisition of Cephalon. The follow-on drug Nuvigil later collapsed after generic entry, and defending the franchise cost Teva a $1.2B antitrust settlement.
Cephalon to acquire Group Lafon for $450 million cash, gaining worldwide rights to Provigil and lowering cost of goods sold; the company framed the deal as…
Sleep Foundation reports ~200,000 Americans have narcolepsy with <50,000 diagnosed; modafinil/armodafinil remain first-line for excessive daytime sleepiness.
Modafinil/Provigil became Cephalon's flagship product post-Lafon acquisition; pre-genericization peak sales exceeded $800M annually before generics in 2012.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon announced agreement Dec 2000 to acquire France's Group Lafon for $450M cash, securing worldwide modafinil (Provigil) rights and the API manufacturing site (Mitry-Mory). Closed in December 2001 after share-purchase amendment.
Assessment window: 5yr post-close.
$80M Cephalon-projected French Lafon product revenue 2002 (~$80M)
Narcolepsy is a chronic neurological disorder of sleep-wake regulation marked by excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations, caused in most cases by hypocretin/orexin neuron loss. Roughly 200,000 Americans are estimated to have it, with fewer than 50,000 diagnosed; first-line therapy is wake-promoting agents.
By late 2000, the wake-promoting market was dominated by traditional psychostimulants — methylphenidate (Ritalin) and dextroamphetamine (Dexedrine, Adderall) — which carried abuse liability, cardiovascular risk, and Schedule II controls. Provigil (modafinil), launched by Cephalon in February 1999 under license from Lafon, was a Schedule IV non-amphetamine wake-promoter with a cleaner side-effect profile, rapidly capturing share in narcolepsy and being prescribed off-label for shift-work disorder, OSA-associated EDS, and ADHD. Cephalon's 2000 deal with Lafon ($450M cash) consolidated worldwide rights and the Mitry-Mory API manufacturing site, eliminating royalty leakage and cutting projected COGS from 22% to 7% of sales — a transformational margin event. The deal also brought European commercial infrastructure and ancillary products (Spasfon, Fonzylane, Olmifon). Robertson Stephens analyst Michael King called it 'a very good financial transaction' enabling more efficient European Provigil ramp. Provigil eventually generated >$800M annual sales pre-genericization (2012), and the franchise extended via Nuvigil (armodafinil) — making the Lafon deal one of the most accretive specialty-pharma acquisitions of its decade. Source: https://www.bioworld.com/articles/391214-cephalon-paying-450m-cash-to-acquire-lafon-provigil-rights
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) (this deal) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2000 deals · Cephalon Inc. deals · Neurology deals